Pharmacodynamic interactions between remifentanil and dexmedetomidine (PIRAD) - PD interaction of REMI and DMED

niversitair Medisch Centrum Groningen0 个研究点目标入组 30 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•- American Society of Anesthesiologists (ASA) Physical Status 1;- No medical history of significance;- No chronic use of medication, drugs, tobacco or more than 20 gr alcohol daily (oral contraceptives excluded). ;- Concerning the cognitive function: Volunteers are considered to have sufficient cognitive reserve if they are able to read and comprehend the patient information form, if they can adequately answer the anamnestic questions during the screening process and if they are allowed to provide legitimate written informed consent. ;- No selection will be made regarding ethnic background;- No exclusion criterium is present

•- Known intolerance to dexmedetomidine or remifentanil;- Volunteer refusal ;- Age < 18 years or >70 years ;- Pregnancy, or currently nursing;- Hairstyle with dreadlocks (EEG-monitoring will not be possible);- Body mass index (BMI) <18 or >30 kg/m2. ;- Neurological disorder (epilepsy, the presence of a brain tumor, a history of brain surgery, hydrocephalic disorders, depression needing treatment with anti-depressive drugs, a history of brain trauma, a subarachnoidal bleeding, TIA or cerebral infarct, psychosis or dementia , schizophrenia, alcohol or drug abuse). ;- Diseases involving the cardiovascular system (hypertension, coronary artery disease, prior acute myocardial infarction, any valvular and/or myocardial disease involving decrease in ejection fraction, arrhythmias, which are either symptomatic or require continuous medication/pacemaker/automatic internal cardioverter defibrillator)
•- Recent use of psycho-active medication (benzodiazepines, anti-epileptic drugs, parkinson medication, anti-depressant drugs, opioids) or more than 20 g of alcohol daily.
•- Bilateral non-patent a. ulnaris
•- Any other condition relevant to the study

发起方